Bevacizumab plus immunotherapy, with interleukin-2 (IL-2) and interferone-alpha (IFN-alpha), plus chemotherapy (BIC), in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial / Buti, S; Lazzarelli, S; Simonelli, C; Venturini, S; Spazzapan, S; Lo Re, G; Mattioli, R; Dalla Chiesa, M; Brighenti, M; Mazza, G; Passalacqua, R. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 18:(2007), pp. 81-81.

Bevacizumab plus immunotherapy, with interleukin-2 (IL-2) and interferone-alpha (IFN-alpha), plus chemotherapy (BIC), in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial

Buti S;
2007

Bevacizumab plus immunotherapy, with interleukin-2 (IL-2) and interferone-alpha (IFN-alpha), plus chemotherapy (BIC), in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial / Buti, S; Lazzarelli, S; Simonelli, C; Venturini, S; Spazzapan, S; Lo Re, G; Mattioli, R; Dalla Chiesa, M; Brighenti, M; Mazza, G; Passalacqua, R. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 18:(2007), pp. 81-81.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2906909
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact